Stelerix Web Blog Knowledge at your Fingertips

15Feb/110

KOL Engagement and Alignment.

Here's a quick excerpt from our Special Comprehensive Country Report, India. It's something we've seen addressed again and again in our follow-up interviews.  I've also thrown in a YouTube interview with Tushar Barad who talks about some of the intricacies of engaging with KOLs.

The updated report will be exclusively available for free through our great friends over at pharmaphorum. So you better get registered!

"Respondents identified active engagement of local Key Opinion Leaders as the most effective means to understand their needs. Further, this strategy provides accurate insight into actual affordability as demonstrated by purchasing power and cost of living, in addition to possible commercial strategies and their respective likelihoods. However, our research also suggested that organizations as a whole have been slow to actively engage end-users. Patience and value on the long term was also a key trend among respondents. It was evident from our results that success in India favors ongoing and long-term relationships that grow and evolve over time. While short-term profit can be made, it is clear that the initial time investment and requisite patience were rewarded many times over when focus was placed on the longer term.  A further benefit of continuous investment in “relationship capital” is the evolution of mutually business partnerships. Organizations who establish themselves effectively in India can often leverage their presence to reach other fast-growing markets in the South-Asian and Asia-Pacific region. Our experts agree that to be effective into 2020 and beyond, market leaders must invest proactively in nascent relationships, given the propensity for longer cycle time in such business partnerships. Opportunity to cut costs and drive access will exist for those who look to partner and aid, rather than exploit."

Posted by Jeff

Oh yeah, the full report will also be available for download here, but this week only!!

9Feb/110

A New Paradigm

It can be tough to sit down and watch a 40 minute interview. People don't have time to make dinner, how are they going to have time to watch something so encompassing?

With that in mind, I've begun breaking down my work into bite-size video portions. I'll post them here, and update the pages on the main site concurrently.

In this short clip, my friend Dr. Gregory Weiss talks about a new paradigm in translational medicine and drug development, based on a comprehensive, global, or combinatorial approach. Watch and learn!

Posted by Jeff

1Feb/110

Common Hurdles.

Here in Canada, we often hear about a potentially-crippling void of innovation. Closer inspection indicates that it isn't for lack of research. In fact, it's a sub-par commercialization process that is culpable for the dropped ball.

This is of course a common theme, but I was surprised to hear it mentioned to me by Kiran Mazumdar Shaw, the Managing Director of India's largest biotechnology company, Biocon. "Scientist entrepreneurs are few and far between - what challenges our scientists in advancing their research into businesses?"

And as all our research is guided by primary interactions with stakeholders, so this will be the guiding question, over the course of the next few interviews. Stay tuned for step-by-step examples of entrepreneurs who have commercialized their developments.